Is it safe?
Can LXRX take a bad year?
Lexicon Pharmaceuticals, Inc. holds $121M more cash than debt, so a bad year is a question about profits, not about lenders.
$121M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- -7.47
Altman Z-score · distress zone, below 1.8
- Debt / equity
- 0.24×
Debt / equity
Details›
- Total debtQ1 2026
- $50M
- Cash and short-term investments
- $171M
- Net cash
- $121M
- EBITDA, trailing twelve months
- −$24M
- Operating profit, trailing twelve months
- −$24M
- Debt / equity
- 0.24×
- Annualised volatilitytwo years of daily moves
- 110%
- Worst drawdown on file
- −99%
- Below its 52-week high
- −7.2%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry